On Monady, Brazil’s health regulator said that it had suspended clinical trials of a Chinese Covid-19 vaccine after an adverse incident involving a volunteer recipient.
The regulator, Anvisa, said in a statement that it had “ruled to interrupt the clinical trial of the CoronaVac vaccine after a serious adverse incident” on October 29.
It said it could not give details on what happened because of privacy regulations, but that such incidents included death, potentially fatal side effects, serious disability, hospitalization, birth defects and other clinically significant events.
